207 related articles for article (PubMed ID: 28926428)
1. DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation?
Ørskov AD; Grønbæk K
Cancer J; 2017; 23(5):277-285. PubMed ID: 28926428
[TBL] [Abstract][Full Text] [Related]
2. [Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk myelodysplastic syndrome].
Maeda Y
Rinsho Ketsueki; 2014 Oct; 55(10):1870-81. PubMed ID: 25297751
[No Abstract] [Full Text] [Related]
3. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
4. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic therapies move into new territory, but how exactly do they work?
Tuma RS
J Natl Cancer Inst; 2009 Oct; 101(19):1300-1. PubMed ID: 19755677
[No Abstract] [Full Text] [Related]
6. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
[No Abstract] [Full Text] [Related]
7. Clinical update on hypomethylating agents.
Duchmann M; Itzykson R
Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
[TBL] [Abstract][Full Text] [Related]
8. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Estey EH
Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
[TBL] [Abstract][Full Text] [Related]
9. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.
Wang R; Gross CP; Maggiore RJ; Halene S; Soulos PR; Raza A; Galili N; Ma X
Leuk Res; 2011 Jul; 35(7):904-8. PubMed ID: 21067809
[TBL] [Abstract][Full Text] [Related]
10. Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Gore SD
J Natl Compr Canc Netw; 2006 Jan; 4(1):83-90. PubMed ID: 16403407
[TBL] [Abstract][Full Text] [Related]
11. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
Merkel DG; Nagler A
Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
[TBL] [Abstract][Full Text] [Related]
12. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
Silverman LR; Mufti GJ
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome.
Tran HT; Kim HN; Lee IK; Kim YK; Ahn JS; Yang DH; Lee JJ; Kim HJ
J Korean Med Sci; 2011 Feb; 26(2):207-13. PubMed ID: 21286011
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
Lübbert M
Curr Top Microbiol Immunol; 2000; 249():135-64. PubMed ID: 10802943
[No Abstract] [Full Text] [Related]
15. Targeting DNA methylation.
Issa JP; Kantarjian HM
Clin Cancer Res; 2009 Jun; 15(12):3938-46. PubMed ID: 19509174
[TBL] [Abstract][Full Text] [Related]
16. DNA Methylation-Targeted Drugs.
Da Costa EM; McInnes G; Beaudry A; Raynal NJ
Cancer J; 2017; 23(5):270-276. PubMed ID: 28926427
[TBL] [Abstract][Full Text] [Related]
17. Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes.
Tohyama K
Curr Pharm Des; 2012; 18(22):3190-7. PubMed ID: 22571698
[TBL] [Abstract][Full Text] [Related]
18. Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents.
Sekeres MA
Leuk Lymphoma; 2015; 56(12):3267-9. PubMed ID: 26077360
[TBL] [Abstract][Full Text] [Related]
19. Use of hypomethylating agents in myelodysplastic syndromes.
Atallah E; Garcia-Manero G
Clin Adv Hematol Oncol; 2007 Jul; 5(7):544-52. PubMed ID: 17679928
[TBL] [Abstract][Full Text] [Related]
20. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.
Roberts DA; Steensma DP
Curr Hematol Malig Rep; 2015 Sep; 10(3):318-28. PubMed ID: 26126600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]